Test a blood/tissue test to sort stage III kidney cancer risk
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial checks whether a CpG-methylation test can help sort people with stage III clear cell kidney cancer who are planning adjuvant (after-surgery) treatment. It may help doctors choose the most appropriate follow-up plan based on your cancer’s risk pattern.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have signed consent to join the study.
- You have confirmed stage III clear cell kidney cancer.
- Your overall health is fairly good (ECOG score 0–1).
- You had your main kidney surgery first, with no cancer at the cut edge (negative margins).
- Before that surgery, you did not receive anti-cancer treatment (like chemo or targeted therapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new scoring system to see if it can help predict the risk of cancer coming back in people with stage III clear cell kidney cancer. If you qualify, the study team will use your medical information to see if this scoring system could help guide future treatment decisions.
This study follows people with newly diagnosed kidney cancer who have not started treatment. It tests whether a special blood test can monitor the cancer over time, alongside standard follow-up after planned surgery.
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
This study is testing whether tracking DNA from your tumor in your blood can help predict how well immunotherapy works for a rare type of kidney cancer called non-clear cell renal cell carcinoma. The goal is to see if this blood test can guide treatment decisions and improve outcomes.
This trial tests a first-line precision treatment for clear cell kidney cancer that has spread or cannot be removed. It aims to match the treatment to your cancer's protein profile to improve outcomes.
This trial is testing whether adding a gut health supplement (CBM588) to the immunotherapy drug pembrolizumab can help prevent kidney cancer from returning after surgery. It is for people with certain types of kidney cancer who have not had immunotherapy before.
Hear when a new Renal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.